EVKEEZA Concentrate for solution for infusion Ref.[27942] Active ingredients: Evinacumab

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Ultragenyx Germany GmbH, Rahel-Hirsch-Str. 10, 10557 Berlin, Germany

Product name and form

Evkeeza 150 mg/ml concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion (sterile concentrate).

Clear to slightly opalescent, colourless to pale yellow sterile solution with a pH of 6.0 and an osmolality of approximately 500 mmol/kg.

Qualitative and quantitative composition

Each ml of concentrate for solution for infusion contains 150 mg of evinacumab.

One vial of 2.3 ml of concentrate contains 345 mg of evinacumab.

One vial of 8 ml of concentrate contains 1,200 mg of evinacumab.

Evinacumab is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Evinacumab

Evinacumab is a recombinant human monoclonal antibody, which specifically binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab blockade of ANGPTL3 lowers TG and HDL-C by releasing LPL and EL activities from ANGPTL3 inhibition, respectively.

List of Excipients

Proline
Arginine hydrochloride
Histidine hydrochloride monohydrate
Polysorbate 80
Histidine
Water for injections

Pack sizes and marketing

2.3 ml of concentrate in a 3 ml clear Type 1 glass vial with a grey chlorobutyl stopper with coating and a seal cap with a flip-off button containing 345 mg of evinacumab. Pack size of 1 vial.

8 ml of concentrate in a 20 ml clear Type 1 glass vial, with a grey chlorobutyl stopper with coating and a seal cap with a flip-off button containing 1 200 mg of evinacumab. Pack size of 1 vial.

Not all pack sizes may be marketed.

Marketing authorization holder

Ultragenyx Germany GmbH, Rahel-Hirsch-Str. 10, 10557 Berlin, Germany

Marketing authorization dates and numbers

EU/1/21/1551/001
EU/1/21/1551/002

Date of first authorisation: 17 June 2021

Drugs

Drug Countries
EVKEEZA Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.